Solid target processing system for 225Ac production
Due to its clinical significance, Targeted Alpha Therapy (TAT) has attracted a special attention.
Actinium-225 (225Ac, α = 100%, T1/2 = 9.92 days) is a promising radionuclide usable for TAT. However, its production on a wide scale is in the development stage, while the global demand has increased. Compared to the worldwide demand of 225Ac, the amount produced via depleted thorium-229 sources is minimal, making it an expensive radionuclide. Alternative production routes (including cyclotrons, reactors and high-energy linear accelerators) are therefore widely desired.
Learn more about Solid target processing system for 225Ac production by filling out the form and downloading the pdf document.
Interested in the difference between isotopes and radioisotopes?
Keen to understand more about nuclear medicine?
Join us for an in-depth exploration, where we share our proven and safe solutions.
Fill out the form to download the PDF document